Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IRAK3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IRAK3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/IRAK3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/IRAK3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IRAK3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
GO:005134834 | Thyroid | ATC | negative regulation of transferase activity | 144/6293 | 268/18723 | 7.63e-12 | 2.91e-10 | 144 |
GO:003298422 | Thyroid | ATC | protein-containing complex disassembly | 121/6293 | 224/18723 | 2.25e-10 | 6.59e-09 | 121 |
GO:007190025 | Thyroid | ATC | regulation of protein serine/threonine kinase activity | 176/6293 | 359/18723 | 8.35e-10 | 2.17e-08 | 176 |
GO:000646925 | Thyroid | ATC | negative regulation of protein kinase activity | 114/6293 | 212/18723 | 1.06e-09 | 2.69e-08 | 114 |
GO:000989529 | Thyroid | ATC | negative regulation of catabolic process | 159/6293 | 320/18723 | 1.61e-09 | 3.99e-08 | 159 |
GO:003367325 | Thyroid | ATC | negative regulation of kinase activity | 122/6293 | 237/18723 | 9.19e-09 | 1.94e-07 | 122 |
GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
GO:004677717 | Thyroid | ATC | protein autophosphorylation | 114/6293 | 227/18723 | 1.54e-07 | 2.49e-06 | 114 |
GO:004217733 | Thyroid | ATC | negative regulation of protein catabolic process | 68/6293 | 121/18723 | 2.66e-07 | 4.08e-06 | 68 |
GO:005109022 | Thyroid | ATC | regulation of DNA-binding transcription factor activity | 190/6293 | 440/18723 | 1.49e-05 | 1.39e-04 | 190 |
GO:000283123 | Thyroid | ATC | regulation of response to biotic stimulus | 144/6293 | 327/18723 | 4.94e-05 | 3.91e-04 | 144 |
GO:004340513 | Thyroid | ATC | regulation of MAP kinase activity | 82/6293 | 177/18723 | 2.87e-04 | 1.83e-03 | 82 |
GO:000222114 | Thyroid | ATC | pattern recognition receptor signaling pathway | 80/6293 | 172/18723 | 2.89e-04 | 1.84e-03 | 80 |
GO:006075912 | Thyroid | ATC | regulation of response to cytokine stimulus | 76/6293 | 162/18723 | 2.92e-04 | 1.85e-03 | 76 |
GO:007190122 | Thyroid | ATC | negative regulation of protein serine/threonine kinase activity | 59/6293 | 120/18723 | 2.95e-04 | 1.87e-03 | 59 |
GO:000195912 | Thyroid | ATC | regulation of cytokine-mediated signaling pathway | 71/6293 | 150/18723 | 3.28e-04 | 2.04e-03 | 71 |
GO:004340926 | Thyroid | ATC | negative regulation of MAPK cascade | 82/6293 | 180/18723 | 5.51e-04 | 3.19e-03 | 82 |
GO:0061082 | Thyroid | ATC | myeloid leukocyte cytokine production | 18/6293 | 28/18723 | 8.70e-04 | 4.72e-03 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IRAK3 | SNV | Missense_Mutation | | c.1312N>A | p.Glu438Lys | p.E438K | Q9Y616 | protein_coding | tolerated(0.09) | probably_damaging(0.941) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
IRAK3 | SNV | Missense_Mutation | novel | c.1330N>A | p.Glu444Lys | p.E444K | Q9Y616 | protein_coding | deleterious(0.01) | possibly_damaging(0.679) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
IRAK3 | SNV | Missense_Mutation | | c.1408T>G | p.Phe470Val | p.F470V | Q9Y616 | protein_coding | tolerated(0.05) | possibly_damaging(0.471) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
IRAK3 | SNV | Missense_Mutation | novel | c.521N>T | p.Gly174Val | p.G174V | Q9Y616 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK3 | SNV | Missense_Mutation | novel | c.1257N>G | p.Phe419Leu | p.F419L | Q9Y616 | protein_coding | tolerated(1) | benign(0.031) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
IRAK3 | SNV | Missense_Mutation | novel | c.632C>T | p.Ser211Phe | p.S211F | Q9Y616 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
IRAK3 | SNV | Missense_Mutation | | c.466N>G | p.Gln156Glu | p.Q156E | Q9Y616 | protein_coding | tolerated(0.47) | benign(0.057) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK3 | SNV | Missense_Mutation | | c.1226N>T | p.Pro409Leu | p.P409L | Q9Y616 | protein_coding | tolerated(0.07) | probably_damaging(0.986) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK3 | deletion | Frame_Shift_Del | | c.592delN | p.Met200CysfsTer26 | p.M200Cfs*26 | Q9Y616 | protein_coding | | | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK3 | SNV | Missense_Mutation | novel | c.591N>T | p.Glu197Asp | p.E197D | Q9Y616 | protein_coding | tolerated(0.25) | possibly_damaging(0.735) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |